

15. (new) The method of claim 10, wherein the administering is by expression of a nucleic acid.

16. (new) The method of claim 10, wherein the wound is an acute wound.

17. (new) The method of claim 10, wherein the wound is a chronic wound.

18. (new) The method of claim 10, wherein the wound is a chronic ulcera.

19. (new) The method of claim 10, wherein the wound is a cutaneous wound.

20. (new) The method of claim 19, wherein the cutaneous wound is from skin loss from burn.

21. (new) The method of claim 10, wherein the wound is a non cutaneous wound.

22. (new) The method of claim 21, wherein the non cutaneous wound is from injury to a stromal tissue.

23. (new) The method of claim 21, wherein the non cutaneous wound is from a surgery.

24. (new) The method of claim 23, wherein the surgery is an abdominal surgery.

25. (new) The method of claim 23, wherein the surgery is a cartilage or a joint surgery.

26. (new) The method of claim 23, wherein the surgery is an oral surgery.

REMARKS

Applicants elect Group III. (Claim 10) without traverse. This claim is directed to a method for treating an individual suffering from a wound comprising administering a cytokine to accelerate wound healing.

In addition, Applicants select lymphotactin among the species of cytokines and cytokine receptors listed by the Examiner.

STATUS OF CLAIMS

Claims 1-9, 11 and 12 are cancelled as they are drawn to non-elected inventions. As a result of the above-mentioned claim cancellations, claim 10 remains pending. Applicants have amended claim 10 for greater clarity and consistency. Support for this claim amendment may be found in the specification (e.g., page 13, lines 7-21) as well as in the originally filed claims.